PRADAXA

A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

  • Product
  • In this atlas

Overview

Technical summary

Drugs@FDA application NDA214358. Original approval 2021-06-21. No efficacy supplement approvals are on record. 6 products listed.

Trials at a glance

No registry trial in this atlas names this product.

Regulatory decisions
1

Product details

Type
Medicine
Model or formulation
Dosage forms in the registry record: PELLETS
Version
Not stated in the openFDA record

Intended-use sources

No intended-use source is recorded.

The registry's words

Labels as the registry gives them, not rewritten.

Application
NDA214358
Brand name
PRADAXA
Applicant
BOEHRINGER INGELHEIM
Active ingredient
DABIGATRAN ETEXILATE MESYLATE
Dosage form
PELLETS
Route
ORAL

Claims and evidence

Context FDA record read by the openFDA feed

Recipient
Recipient not specified
Population
Not stated in the openFDA record
Care setting
Not stated in the openFDA record
Geography
United States (a decision by the US Food and Drug Administration)
Life stage
Not stated in the openFDA record
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Regulatory Evidence stage not applicable Certainty not assessed

    FDA records an approval of NDA214358 on 2021-06-21.

    Applies to Recipient not specified FDA record read by the openFDA feed

    Certainty method
    Not assessed
    Limitations
    Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
    Last checked
    Not recorded
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports Drugs@FDA application NDA214358 (openFDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · NDA: NDA214358

      Locator
      submissions[0].submission_status_date
      How it applies
      The decision date as the record writes it.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
    2. Supports Drugs@FDA application NDA214358 (openFDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · NDA: NDA214358

      Locator
      application_number
      How it applies
      The registry number of the record.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
    3. Supports Drugs@FDA application NDA214358 (openFDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · NDA: NDA214358

      Locator
      submissions[0].submission_status
      How it applies
      The decision status as the record writes it.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee45b8b2133853e3cf8f2c96c08e944707321e4ebbdcf6aa93fe218d7b20478b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.

FDA label

Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for this product: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.

Application
NDA214358
Labeler
Boehringer Ingelheim Pharmaceuticals, Inc.
Label version
Version 7, effective
Label set id
9ac0a64a-8666-45f7-9d4f-40fd894f7e6d
Boxed warning
Yes
Sections the label has
Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this product, oldest first. Each links to its full record.

  1. Approval NDA214358

Authorization

Regulatory decision: PRADAXA

Applies to Recipient not specified
  • Not stated in the openFDA record
  • Not stated in the openFDA record
  • United States (a decision by the US Food and Drug Administration)
  • Not stated in the openFDA record
  • Gestational age Not reported
  • Postnatal age Not reported
Follow-up Not applicable (regulatory decision)
Decision
Approval,
Pathway
NDA
Submission
NDA214358
Jurisdictions
United States
Product version
Original application
Indication
Not stated in the openFDA record
Basis
FDA records an approval of NDA214358 on 2021-06-21.

Limitations. Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.

A regulatory decision is separate from a guideline recommendation and from payment coverage.

Record details

Record id
cardio:fdaprod-nda214358
Content hash
fd73e9f0e7e043ff4a58f9fade0d6a6018d808dab56eed761333f662283bc5cb